$50.1 Million is the total value of OUP Management Co., LLC's 14 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AVTE | Aerovate Therapeutics Inc. | $12,177,880 | -31.2% | 603,762 | 0.0% | 24.30% | -15.8% | |
| CNTA | Centessa Pharmaceuticals plcsponsored ads | $11,309,818 | +24.2% | 2,937,615 | 0.0% | 22.57% | +51.8% | |
| DICE Therapeutics Inc. | $7,688,113 | -8.2% | 268,346 | 0.0% | 15.34% | +12.3% | ||
| PMVP | PMV Pharmaceuticals, Inc. | $4,718,637 | -45.2% | 989,232 | 0.0% | 9.42% | -33.0% | |
| CYT | Cyteir Therapeutics, Inc. | $4,476,421 | +10.3% | 2,459,572 | 0.0% | 8.93% | +34.8% | |
| Sell | ionQ, Inc. | $2,396,458 | -41.0% | 389,668 | -66.9% | 4.78% | -27.9% | |
| VOR | Vor Biopharma Inc. | $2,015,961 | -19.1% | 374,714 | 0.0% | 4.02% | -1.1% | |
| Prime Medicine, Inc. | $1,491,437 | -33.8% | 121,255 | 0.0% | 2.98% | -19.1% | ||
| SELB | Selecta Biosciences, Inc. | $1,198,935 | +23.0% | 862,543 | 0.0% | 2.39% | +50.4% | |
| GRPH | Graphite Bio | $995,455 | -26.2% | 406,308 | 0.0% | 1.99% | -9.8% | |
| DTIL | Precision BioSciences, Inc. | $846,981 | -36.7% | 1,123,913 | 0.0% | 1.69% | -22.6% | |
| eFFECTOR Therapeutics, Inc. | $361,763 | -17.5% | 1,025,697 | 0.0% | 0.72% | +0.8% | ||
| SPRO | Spero Therapeutics, Inc. | $361,152 | -16.2% | 249,070 | 0.0% | 0.72% | +2.6% | |
| FIXX | Homology Medicines, Inc. | $65,920 | -18.3% | 64,000 | 0.0% | 0.13% | 0.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-04-24
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Centessa Pharmaceuticals plc | 8 | Q3 2023 | 42.7% |
| Aerovate Therapeutics Inc. | 8 | Q3 2023 | 28.9% |
| PMV Pharmaceuticals, Inc. | 8 | Q3 2023 | 19.4% |
| Cyteir Therapeutics, Inc. | 8 | Q3 2023 | 15.7% |
| Vor Biopharma Inc. | 8 | Q3 2023 | 4.1% |
| Precision BioSciences, Inc. | 8 | Q3 2023 | 3.7% |
| Graphite Bio | 8 | Q3 2023 | 2.3% |
| eFFECTOR Therapeutics, Inc. | 8 | Q3 2023 | 3.8% |
| Selecta Biosciences, Inc. | 8 | Q3 2023 | 2.4% |
| Spero Therapeutics, Inc. | 8 | Q3 2023 | 1.8% |
View OUP Management Co., LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-11-09 |
| 13F-HR | 2023-08-07 |
| 13F-HR | 2023-04-24 |
| 13F-HR | 2023-02-02 |
| 13F-HR | 2022-11-01 |
| 13F-HR | 2022-07-19 |
| 13F-HR | 2022-05-04 |
| 13F-HR | 2022-02-03 |
View OUP Management Co., LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.